Firm fixed price award center for drug evaluation and research (cder)-biosimilar user fee act i program biosimilar and interchangeable product education, uptake, and implementation FDA…
Ended Awarded Last action
- Contract number
- 75F40120F19029
- Awardee
-
Booz Allen Hamilton Inc. UEI JCBMLGPE6Z71 Part of Booz Allen Hamilton Holding Corporation
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $999,836
Award facts
- Contract value 100% obligated
- $999,836.08 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541611 Administrative Management and General Management Consulting Services
- PSC
- R499 Support- Professional: Other
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Rockville, MD 20857, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $999,836 |
About this award
Booz Allen Hamilton Inc. was awarded a firm fixed price contract valued at $999,836.08 by the Department of Health and Human Services' Food and Drug Administration to provide services under the Center for Drug Evaluation and Research's Biosimilar User Fee Act Program. Specifically, Booz Allen Hamilton will support biosimilar and interchangeable product education, uptake, and implementation efforts. The contract was awarded through the Mission Oriented Business Integrated Services Governmentwide Acquisition Contract and has a period of performance through December 31, 2021. No set-aside designation was utilized for this award to Booz Allen Hamilton, which will perform associated services in Rockville, Maryland.
Description
Firm fixed price award center for drug evaluation and research (cder)-biosimilar user fee act i program biosimilar and interchangeable product education, uptake, and implementation FDA three-way-matching invoice clause-COR
Quick answers
Who was awarded contract 75F40120F19029?
75F40120F19029 was awarded to Booz Allen Hamilton Inc. by Food and Drug Administration (Department of Health and Human Services) on May 21, 2020.
How much is contract 75F40120F19029 worth?
The government has obligated $999,836 on 75F40120F19029.
Is contract 75F40120F19029 an order under another contract?
Yes. 75F40120F19029 is a BPA call under GS23F9755H-HHSF223201510027B, a blanket purchase agreement, on Mission Oriented Business Integrated Services (MOBIS).
Was contract 75F40120F19029 competed?
The extent of competition for 75F40120F19029 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award